Shenzhen Salubris May Acquire Liver Cancer Candidate from US NIH

01:17 EDT 10 Aug 2017 | ChinaBio Today

Salubris Biotherapeutics, the US arm of Shenzhen Salubris Pharma, has negotiated a tech transfer with the US National Institutes of Health for a potential liver cancer drug. The rights are for a bispecific antibody-drug conjugate targeting GPC3, an antigen expressed in liver cancer. According to the NIH, opponents have until August 22 to object to the agreement; otherwise, it will proceed. Some elected US officials oppose these agreements, arguing the US government paid for the basic research, but retains no control over the price the licensee will charge. More details....

Stock Symbol: (SZE: 2294)

Share this with colleagues:

Original Article: Shenzhen Salubris May Acquire Liver Cancer Candidate from US NIH


More From BioPortfolio on "Shenzhen Salubris May Acquire Liver Cancer Candidate from US NIH"

Quick Search

Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...